500 related articles for article (PubMed ID: 28458525)
21. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK
Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310
[TBL] [Abstract][Full Text] [Related]
22. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
Rakonczay Z
Acta Biol Hung; 2003; 54(2):183-9. PubMed ID: 14535624
[TBL] [Abstract][Full Text] [Related]
23. Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer's Disease-Could
Jasiecki J; Wasąg B
Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31601022
[No Abstract] [Full Text] [Related]
24. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
Greig NH; Lahiri DK; Sambamurti K
Int Psychogeriatr; 2002; 14 Suppl 1():77-91. PubMed ID: 12636181
[TBL] [Abstract][Full Text] [Related]
25. The ABC of Alzheimer's disease: behavioral symptoms and their treatment.
Grossberg GT
Int Psychogeriatr; 2002; 14 Suppl 1():27-49. PubMed ID: 12636179
[TBL] [Abstract][Full Text] [Related]
26. Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice.
Furukawa-Hibi Y; Alkam T; Nitta A; Matsuyama A; Mizoguchi H; Suzuki K; Moussaoui S; Yu QS; Greig NH; Nagai T; Yamada K
Behav Brain Res; 2011 Nov; 225(1):222-9. PubMed ID: 21820013
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease.
Darvesh S; Walsh R; Kumar R; Caines A; Roberts S; Magee D; Rockwood K; Martin E
Alzheimer Dis Assoc Disord; 2003; 17(2):117-26. PubMed ID: 12794390
[TBL] [Abstract][Full Text] [Related]
28. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action.
Poirier J
Int J Clin Pract Suppl; 2002 Jun; (127):6-19. PubMed ID: 12139368
[TBL] [Abstract][Full Text] [Related]
29. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
Inglis F
Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
[TBL] [Abstract][Full Text] [Related]
30. Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.
Darvesh S; Arora RC; Martin E; Magee D; Hopkins DA; Armour JA
Exp Neurol; 2004 Aug; 188(2):461-70. PubMed ID: 15246845
[TBL] [Abstract][Full Text] [Related]
31. Acetylcholinesterase Enzyme Inhibitor Molecules with Therapeutic Potential for Alzheimer's Disease.
Sivaraman B; Raji V; Velmurugan BA; Natarajan R
CNS Neurol Disord Drug Targets; 2022; 21(5):427-449. PubMed ID: 34602041
[TBL] [Abstract][Full Text] [Related]
32. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
[TBL] [Abstract][Full Text] [Related]
33. Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis.
Weintraub D; Somogyi M; Meng X
Am J Alzheimers Dis Other Demen; 2011 Sep; 26(6):443-9. PubMed ID: 22009228
[TBL] [Abstract][Full Text] [Related]
34. Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study.
Moretti R; Torre P; Antonello RM; Cazzato G; Griggio S; Ukmar M; Bava A
Int J Clin Pract; 2004 Apr; 58(4):346-53. PubMed ID: 15161118
[TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina.
Amici S; Lanari A; Romani R; Antognelli C; Gallai V; Parnetti L
Mech Ageing Dev; 2001 Nov; 122(16):2057-62. PubMed ID: 11589922
[TBL] [Abstract][Full Text] [Related]
36. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans.
Kennedy JS; Polinsky RJ; Johnson B; Loosen P; Enz A; Laplanche R; Schmidt D; Mancione LC; Parris WC; Ebert MH
J Clin Psychopharmacol; 1999 Dec; 19(6):513-21. PubMed ID: 10587286
[TBL] [Abstract][Full Text] [Related]
37. [Acetylcholinesterase inhibitors--beyond Alzheimer's disease].
Kłoszewska I
Psychiatr Pol; 2002; 36(6 Suppl):133-41. PubMed ID: 12647432
[TBL] [Abstract][Full Text] [Related]
38. Treatment of vascular dementia-evidence from clinical trials with cholinesterase inhibitors.
Erkinjuntti T; Román G; Gauthier S
Neurol Res; 2004 Jul; 26(5):603-5. PubMed ID: 15265282
[TBL] [Abstract][Full Text] [Related]
39. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R;
Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010
[TBL] [Abstract][Full Text] [Related]
40. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R
Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
